Sarcomatoid Diffuse Pleural Mesothelioma in an 80-Year-Old Woman with Long-Term Response to Nivolumab Plus Ipilimumab: A Case Report

IF 0.8 Q4 RESPIRATORY SYSTEM

Respiratory Medicine Case Reports Pub Date : 2025-06-26 DOI:10.1016/j.rmcr.2025.102242

Yukiko Yoshida , Hidenori Mizugaki , Yuma Sato , Ken Kuwahara , Noriyuki Yamada , Hajime Asahina , Hiroshi Yokouchi , Yoshihiro Matsuno , Satoshi Oizumi

{"title":"Sarcomatoid Diffuse Pleural Mesothelioma in an 80-Year-Old Woman with Long-Term Response to Nivolumab Plus Ipilimumab: A Case Report","authors":"Yukiko Yoshida , Hidenori Mizugaki , Yuma Sato , Ken Kuwahara , Noriyuki Yamada , Hajime Asahina , Hiroshi Yokouchi , Yoshihiro Matsuno , Satoshi Oizumi","doi":"10.1016/j.rmcr.2025.102242","DOIUrl":null,"url":null,"abstract":"<div><div>An 80-year-old woman presented to our hospital with the chief complaint of left lateral thoracic pain. Chest computed tomography showed multiple nodular lesions in the left pleura and massive left pleural effusion. Based on clinical findings, imaging, and thoracoscopic pleural biopsy, a diagnosis of sarcomatoid diffuse pleural mesothelioma clinical T2N0M0 Stage IB was made. We administered nivolumab plus ipilimumab as first-line treatment, which resulted in significant reduction of pleural lesions and complete resolution of pleural effusion after two courses. No immune-mediated adverse events except fever were observed. Treatment was discontinued after 16 courses, with no disease recurrence for more than 2 years following the initial treatment. This case suggests that nivolumab plus ipilimumab can be an effective treatment option for older adults with pleural mesothelioma who maintain a good performance status.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"56 ","pages":"Article 102242"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213007125000784","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

An 80-year-old woman presented to our hospital with the chief complaint of left lateral thoracic pain. Chest computed tomography showed multiple nodular lesions in the left pleura and massive left pleural effusion. Based on clinical findings, imaging, and thoracoscopic pleural biopsy, a diagnosis of sarcomatoid diffuse pleural mesothelioma clinical T2N0M0 Stage IB was made. We administered nivolumab plus ipilimumab as first-line treatment, which resulted in significant reduction of pleural lesions and complete resolution of pleural effusion after two courses. No immune-mediated adverse events except fever were observed. Treatment was discontinued after 16 courses, with no disease recurrence for more than 2 years following the initial treatment. This case suggests that nivolumab plus ipilimumab can be an effective treatment option for older adults with pleural mesothelioma who maintain a good performance status.

查看原文本刊更多论文

一例80岁女性肉瘤样弥漫性胸膜间皮瘤对尼伏单抗加伊匹单抗长期有反应：一例报告

一位80岁的妇女以左胸廓外侧疼痛为主诉来到我院。胸部电脑断层显示左胸膜多发结节状病变及大量左胸膜积液。根据临床表现，影像学和胸腔镜胸膜活检，诊断为肉瘤样弥漫性胸膜间皮瘤临床T2N0M0期IB。我们将纳武单抗加伊匹单抗作为一线治疗，两个疗程后，胸膜病变显著减少，胸膜积液完全消除。除发热外，未观察到免疫介导的不良反应。16个疗程后停止治疗，初始治疗后2年多无疾病复发。本病例提示，对于保持良好运动状态的老年胸膜间皮瘤患者，纳伏单抗加伊匹单抗是一种有效的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊